Elevance Health (ELV) came out with quarterly earnings of $8.37 per share, missing the Zacks Consensus Estimate of $9.70 per share. This compares to earnings of $8.99 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -13.71%. A quarter ago, it was expected that this health insurer would post earnings of $9.99 per share when it actually produced earnings of $10.12, delivering a surprise of 1.30%. Over the last four quarters, the ...

E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS THIRD QUARTER 2024 RESULTS • 3Q 2024 operating revenue of $44.7 billion 1 • 3Q 2024 adjusted operating gain of $2.4 billion 2 1 • 3Q 2024 diluted EPS of $4.36; adjusted diluted EPS of $8.37 • 4Q 2024 dividend of $1.63 per share declared to shareholders Indianapolis, IN - October 17, 2024 - Elevance Health, Inc. (NYSE: ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigat ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Elevance Health (ELV) , which belongs to the Zacks Medical Services industry. This health insurer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 1.13%. For the last reported quarter, Elevance Health came out with earnings of $10.12 per share versus t ...

Elevance Health, Inc. (ELV) is set to report its third-quarter 2024 results on Oct. 17, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings and revenues is pegged at $9.74 per share and $43.2 billion, respectively. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The earnings estimate for the to-be-reported quarter has witnessed downward revisions over the past 60 days. The bottom-line projection indicates year-over-year growth of 8. ...

In its upcoming report, Elevance Health (ELV) is predicted by Wall Street analysts to post quarterly earnings of $9.74 per share, reflecting an increase of 8.3% compared to the same period last year. Revenues are forecasted to be $43.23 billion, representing a year-over-year increase of 1.8%. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ...

Thanks for reading! We look for high quality stocks trading at attractive valuations in our Marketplace service entitled Cash Flow Compounders: The Best Stocks in the World. Our focus is high return on equity, high free cash flow stocks with a proven track record in compounding earnings at higher than market rates. There we provide in depth research, with 2-4 new, high quality ideas per month. Our ideas have earned returns well above benchmark levels over many years. Sign up for a free 2 week trial to get m ...

Elevance Health, Inc. (ELV) is well-poised to grow on the back of Carelon's business strength and commercial member growth. The company keeps expanding its operating margins for both Health Benefits and Carelon units, which positions it for improving profits. Elevance Health — with a market cap of $114.2 billion — is a major health benefits company. Courtesy of solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment. Let's delve deeper. ELV's One-Year Price Performanc ...

Elevance Health, Inc. (ELV) is well-poised to grow on the back of Carelon's business strength and commercial member growth. The company keeps expanding its operating margins for both Health Benefits and Carelon units, which positions it for improving profits. Elevance Health — with a market cap of $129.1 billion — is a major health benefits company. Courtesy of solid prospects, this presently Zacks Rank #3 (Hold) stock is worth retaining at the moment. Let's delve deeper. ELV YTD Price Performance Shares of ...

Core Viewpoint - Elevance Health reported a strong Q2 2024 earnings performance, with adjusted earnings per share surpassing estimates, although operating revenues showed a slight decline year over year. The company faces challenges with membership attrition in Medicaid, impacting overall margins and premium revenues [2][3][4]. Financial Performance - Adjusted earnings for Q2 2024 were $10.12 per share, exceeding the Zacks Consensus Estimate by 1.3% and reflecting a 12% year-over-year improvement [2]. - Operating revenues totaled $43.2 billion, a decrease of 0.4% year over year, but still beating the consensus mark by 0.5% [2]. - Total expenses were $40.9 billion, down 0.8% year over year, attributed to lower benefit expenses [6]. Membership and Revenue Breakdown - Medical membership stood at approximately 45.8 million, down 5% year over year, missing estimates [4]. - Premium revenues decreased by 3.2% year over year to $35.4 billion, falling short of consensus estimates [5]. - Product revenues increased by 13.8% year over year to $5.5 billion, exceeding expectations [5]. Segment Performance - Health Benefits segment revenues were $37.2 billion, down 2.2% year over year, with an operating gain of $2.1 billion [7]. - Carelon segment revenues rose 10% year over year to $13.3 billion, driven by new services and acquisitions [8]. - Corporate & Other segment revenues improved by 8.9% year over year to $122 million, with a reduced operating loss [10]. Financial Position - As of June 30, 2024, cash and cash equivalents were $6.5 billion, with total assets at $113 billion [11]. - Long-term debt increased by 5.7% to $24.6 billion, while total equity rose by 7.3% to $42.3 billion [11][12]. - The company generated net cash flow from operations of $2.4 billion in the first half of 2024, down from $8.4 billion in the prior year [12]. Capital Deployment - Elevance Health repurchased shares worth $462 million in Q2 2024, with a remaining buyback capacity of approximately $3.2 billion [13]. - The company paid a quarterly dividend of $1.63 per share, totaling $378 million [13]. 2024 Outlook - Adjusted earnings are projected to be at least $37.20 per share, indicating a 12% increase from 2023 [14]. - Operating revenues are expected to show flat to low single-digit growth, with premium revenues anticipated to remain stable [15]. - Medical enrollment is forecasted to be between 45.8 and 46.6 million [15].

FCF on the other hand stands at a meager $516 million for the TTM. However, as I always highlight when performing analysis on these kinds of beath insurance stocks: FCF is very volatile for these companies, so we have to gauge what I call a "normalized" FCF. "Normalized" FCF is the anoount of FCF ELV should be able to generate in an average year. In my last article, I calculated that ELV was able to convert 85% of EBIT into FCF (on average) for the fiscal years 2016-2022. I wil just use this conversion rati ...